Tips Offered for Patient-Provider Opioid Tapering Talks

This article originally appeared here.
Share this content:
Tips Offered for Patient-Provider Opioid Tapering Talks
Tips Offered for Patient-Provider Opioid Tapering Talks

THURSDAY, Dec. 28, 2017 (HealthDay News) -- Helping patients understand individualized reasons for opioid tapering and encouraging them to provide input into the process are key for patient-provider communications, according to a study published in the November issue of the Journal of Pain.

Marianne S. Matthias, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues qualitatively analyzed patient-physician communications to understand communication processes related to opioid tapering in order to identify best practices and opportunities for improvement. As many as three clinic visits per patient were audio-recorded, and interviews with patients and their providers were conducted.

The researchers identified four major themes from these conversations: (1) explaining -- patients needed to understand individualized reasons for tapering in addition to general, population-level concerns; (2) negotiating -- patients needed to have input, even if it was just related to the rate of tapering; (3) managing difficult conversations -- when patients and providers failed to reach a shared understanding, difficulties and misunderstandings arose; and (4) nonabandonment -- patients needed to know that their providers would not abandon them throughout the tapering process.

"Although opioid tapering can be challenging, helping patients to understand individualized reasons for tapering, encouraging patients to have input into the process, and assuring patients they would not be abandoned all appear to facilitate optimal communication about tapering," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »